[
  {
    "ts": "2026-02-10T13:32:00+00:00",
    "headline": "Here's What Will Drive AbbVie's Top-line Growth in 2026",
    "summary": "ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.",
    "url": "https://finance.yahoo.com/news/heres-drive-abbvies-top-line-133200185.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d5ce5f2c-6f21-3316-a124-99ee64b1d098",
      "content": {
        "id": "d5ce5f2c-6f21-3316-a124-99ee64b1d098",
        "contentType": "STORY",
        "title": "Here's What Will Drive AbbVie's Top-line Growth in 2026",
        "description": "",
        "summary": "ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.",
        "pubDate": "2026-02-10T13:32:00Z",
        "displayTime": "2026-02-10T13:32:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OQG3.5Wd9P9R69q2rhm9rA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pBlncPVBhEXpjxtBDlEOsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-drive-abbvies-top-line-133200185.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-drive-abbvies-top-line-133200185.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T15:59:35+00:00",
    "headline": "Jim Cramer on AstraZeneca: “We Want Every Drug Stock”",
    "summary": "AstraZeneca PLC (NASDAQ:AZN) is one of the stocks in focus on Jim Cramer’s game plan. Cramer mentioned the company during the episode and said: On Tuesday, we’re back in heavy earnings rotation. We’ve got DuPont, Coca-Cola, CVS Health, AstraZeneca, Datadog, and S&P Global report… Oh, also, AstraZeneca, we want every drug stock. They’re all working. […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-astrazeneca-want-every-155935662.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "4a4feab5-04d6-3788-adeb-ca648448e570",
      "content": {
        "id": "4a4feab5-04d6-3788-adeb-ca648448e570",
        "contentType": "STORY",
        "title": "Jim Cramer on AstraZeneca: “We Want Every Drug Stock”",
        "description": "",
        "summary": "AstraZeneca PLC (NASDAQ:AZN) is one of the stocks in focus on Jim Cramer’s game plan. Cramer mentioned the company during the episode and said: On Tuesday, we’re back in heavy earnings rotation. We’ve got DuPont, Coca-Cola, CVS Health, AstraZeneca, Datadog, and S&P Global report… Oh, also, AstraZeneca, we want every drug stock. They’re all working. […]",
        "pubDate": "2026-02-10T15:59:35Z",
        "displayTime": "2026-02-10T15:59:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c8ee52b6774570cdbeb59bbfa630f663",
          "originalWidth": 1920,
          "originalHeight": 2880,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w6qL.E8tj9dC2c4ZX8uqew--~B/aD0yODgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/c8ee52b6774570cdbeb59bbfa630f663.cf.webp",
              "width": 1920,
              "height": 2880,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1XpEPoUD_ujb7O_KxwOPnw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c8ee52b6774570cdbeb59bbfa630f663.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-astrazeneca-want-every-155935662.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-astrazeneca-want-every-155935662.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "DD"
            },
            {
              "symbol": "KO"
            },
            {
              "symbol": "CVS"
            },
            {
              "symbol": "DDOG"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T15:29:43+00:00",
    "headline": "AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals",
    "summary": "AbbVie’s latest agreement with the Trump administration underscores a major shift in US drug pricing policy, one in which domestic manufacturing is no longer a peripheral concern but it is built into the deal itself.",
    "url": "https://www.pharmaceutical-technology.com/analyst-comment/abbvie-100bn-deal-domestic-manufacturing/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "d6a1f343-1f7e-3c40-9220-d302571b3219",
      "content": {
        "id": "d6a1f343-1f7e-3c40-9220-d302571b3219",
        "contentType": "STORY",
        "title": "AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals",
        "description": "",
        "summary": "AbbVie’s latest agreement with the Trump administration underscores a major shift in US drug pricing policy, one in which domestic manufacturing is no longer a peripheral concern but it is built into the deal itself.",
        "pubDate": "2026-02-10T15:29:43Z",
        "displayTime": "2026-02-10T15:29:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/386efa40d2e72ff4eee33697f78a6b6b",
          "originalWidth": 1440,
          "originalHeight": 958,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BljOk2Tj_0iDXx76wjH4oA--~B/aD05NTg7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/386efa40d2e72ff4eee33697f78a6b6b.cf.webp",
              "width": 1440,
              "height": 958,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/63xgvwawBZtJv00MVm0iQw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/386efa40d2e72ff4eee33697f78a6b6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/analyst-comment/abbvie-100bn-deal-domestic-manufacturing/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-100bn-deal-aligns-drug-152943387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T14:00:06+00:00",
    "headline": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-attracting-investor-140006364.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "4d35e5c2-be20-3fcd-8332-51e3df3891cb",
      "content": {
        "id": "4d35e5c2-be20-3fcd-8332-51e3df3891cb",
        "contentType": "STORY",
        "title": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
        "description": "",
        "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
        "pubDate": "2026-02-10T14:00:06Z",
        "displayTime": "2026-02-10T14:00:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9",
          "originalWidth": 1000,
          "originalHeight": 754,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ySW4yppQRAB0XpI0aj_Aag--~B/aD03NTQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9.cf.webp",
              "width": 1000,
              "height": 754,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y7O9v2FlH8hDflZpTNqGwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-attracting-investor-140006364.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-attracting-investor-140006364.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]